638 related articles for article (PubMed ID: 22634452)
1. Cholera vaccine: new preventive tool for endemic countries.
Verma R; Khanna P; Chawla S
Hum Vaccin Immunother; 2012 May; 8(5):682-4. PubMed ID: 22634452
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.
Sur D; Lopez AL; Kanungo S; Paisley A; Manna B; Ali M; Niyogi SK; Park JK; Sarkar B; Puri MK; Kim DR; Deen JL; Holmgren J; Carbis R; Rao R; Nguyen TV; Donner A; Ganguly NK; Nair GB; Bhattacharya SK; Clemens JD
Lancet; 2009 Nov; 374(9702):1694-702. PubMed ID: 19819004
[TBL] [Abstract][Full Text] [Related]
3. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.
Anh DD; Canh DG; Lopez AL; Thiem VD; Long PT; Son NH; Deen J; von Seidlein L; Carbis R; Han SH; Shin SH; Attridge S; Holmgren J; Clemens J
Vaccine; 2007 Jan; 25(6):1149-55. PubMed ID: 17055622
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
[TBL] [Abstract][Full Text] [Related]
7. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial.
Bhattacharya SK; Sur D; Ali M; Kanungo S; You YA; Manna B; Sah B; Niyogi SK; Park JK; Sarkar B; Puri MK; Kim DR; Deen JL; Holmgren J; Carbis R; Dhingra MS; Donner A; Nair GB; Lopez AL; Wierzba TF; Clemens JD
Lancet Infect Dis; 2013 Dec; 13(12):1050-6. PubMed ID: 24140390
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera.
Murray J; McFarland DA; Waldman RJ
Bull World Health Organ; 1998; 76(4):343-52. PubMed ID: 9803585
[TBL] [Abstract][Full Text] [Related]
9. Vibrio cholerae: lessons for mucosal vaccine design.
Bishop AL; Camilli A
Expert Rev Vaccines; 2011 Jan; 10(1):79-94. PubMed ID: 21162623
[TBL] [Abstract][Full Text] [Related]
10. [Anticholera vaccines and vaccination].
Ivanoff B; Chaignat CL
Bull Soc Pathol Exot; 2002 Dec; 95(5):355-8. PubMed ID: 12696375
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.
Charles RC; Hilaire IJ; Mayo-Smith LM; Teng JE; Jerome JG; Franke MF; Saha A; Yu Y; Kováč P; Calderwood SB; Ryan ET; LaRocque RC; Almazor CP; Qadri F; Ivers LC; Harris JB
PLoS Negl Trop Dis; 2014 May; 8(5):e2828. PubMed ID: 24786645
[TBL] [Abstract][Full Text] [Related]
12. Questionable merits of the field trial of an oral killed whole cell cholera vaccine in Vietnam during 1998-2003.
Kabir S
Vaccine; 2007 Feb; 25(8):1353-4. PubMed ID: 17049687
[No Abstract] [Full Text] [Related]
13. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam.
Trach DD; Clemens JD; Ke NT; Thuy HT; Son ND; Canh DG; Hang PV; Rao MR
Lancet; 1997 Jan; 349(9047):231-5. PubMed ID: 9014909
[TBL] [Abstract][Full Text] [Related]
14. [Cholera update and vaccination problems].
Fournier JM; Villeneuve S
Med Trop (Mars); 1998; 58(2 Suppl):32-5. PubMed ID: 9812307
[TBL] [Abstract][Full Text] [Related]
15. Cholera vaccines for the developing world.
Lopez AL; Clemens JD; Deen J; Jodar L
Hum Vaccin; 2008; 4(2):165-9. PubMed ID: 18414029
[TBL] [Abstract][Full Text] [Related]
16. Cholera outbreaks in Africa.
Mengel MA; Delrieu I; Heyerdahl L; Gessner BD
Curr Top Microbiol Immunol; 2014; 379():117-44. PubMed ID: 24827501
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology & molecular biology of Vibrio cholerae O139 Bengal.
Albert MJ
Indian J Med Res; 1996 Jul; 104():14-27. PubMed ID: 8783504
[TBL] [Abstract][Full Text] [Related]
18. Cholera: a new homeland in Africa?
Gaffga NH; Tauxe RV; Mintz ED
Am J Trop Med Hyg; 2007 Oct; 77(4):705-13. PubMed ID: 17978075
[TBL] [Abstract][Full Text] [Related]
19. A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia.
Desai SN; Akalu Z; Teshome S; Teferi M; Yamuah L; Kim DR; Yang JS; Hussein J; Park JY; Jang MS; Mesganaw C; Taye H; Beyene D; Bedru A; Singh AP; Wierzba TF; Aseffa A
Am J Trop Med Hyg; 2015 Sep; 93(3):527-533. PubMed ID: 26078323
[TBL] [Abstract][Full Text] [Related]
20. Cholera in Africa: new momentum in fighting an old problem.
Mengel MA
Trans R Soc Trop Med Hyg; 2014 Jul; 108(7):391-2. PubMed ID: 24836060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
